Other Information
−Removed: None of our directors or executive officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement during the quarter ended March 31, 2026, as such terms are defined under Item 408 (a) of Regulation S-K.
−Removed: Additionally, we did not adopt or terminate a Rule 10b5 - 1 trading arrangement during the quarter ended March 31, 2026.
+Added: None of our directors or executive officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement during the three and six months ended June 30, 2026, as such terms are defined under Item 408 (a) of Regulation S-K.
+Added: Additionally, we did not adopt or terminate a Rule 10b5 - 1 trading arrangement during the three and six months ended June 30, 2026.
+Added: Amendment No.
+Added: 1 to the NRx Pharmaceuticals, Inc.
+Added: 2021 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 24, 2026)
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
NRX PHARMACEUTICALS, INC.
+Added: August 14, 2026
/s/ Jonathan Javitt
3 unchanged sentences
NRX PHARMACEUTICALS, INC.
+Added: August 14, 2026
/s/ Michael Abrams
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.